Such finding could provide insights into new drug targets for rectal cancer similar to the inhibition of NF-κB dependent intestinal inflammation attained by targeting an enteroglial-specific protein/TLR4 axis that demonstrated therapeutic effects in ulcerative colitis [71]. This evidence concerns the gene TLR4 and ulcerative colitis.